MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
The authors of this phase Ib trial evaluated the oral IDH1 inhibitor ivosidenib in combination with azacitidine in 23 patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy. The overall and complete response rates were 78% and 61%, respectively. The median duration of response and median overall survival were not yet reached […]
